This Week in Pediatrics — Aug 17, 2026

Welcome to This Week in Pediatrics. This week we're covering 10 notable papers spanning infectious disease prevention and treatment, neonatal and developmental care, and a cluster of studies that help us decide when to intervene and when to hold back. Let's dive in.

We'll start with respiratory infections, where two papers together sketch out the modern playbook. In Pediatrics, Huang and colleagues report a multicentre, age- and season-matched case-control study of nearly fifteen hundred children with laboratory-confirmed influenza seen as outpatients across three seasons from 2020 to 2023, comparing 354 children later hospitalised or dead from influenza with more than eleven hundred matched non-hospitalised controls. Antiviral therapy started within forty-eight hours of symptom onset was associated with an eighty-one percent lower risk of subsequent hospitalisation, and the protection was essentially identical in children five years and younger as in older children [1]. This is observational data, so treatment-seeking behaviour and unmeasured severity could bias the estimate, but the authors report E-values around ten, meaning an unmeasured confounder would have to be implausibly strong to explain the result away. The practical message is unglamorous and important: when a child presents inside the forty-eight-hour window with influenza, prescribe promptly rather than waiting to see how things evolve. On the prevention side, Acta Paediatrica carries a concise review from Heinonen and Vartiainen on the new era of respiratory syncytial virus immunoprophylaxis. Three products have been approved since 2022: the long-acting monoclonal antibodies nirsevimab and clesrovimab, and a maternal vaccine. Across pivotal trials, efficacy ranged from roughly half to about three quarters against medically attended lower respiratory tract infection, and from about fifty-five percent up to ninety-one percent against respiratory syncytial virus hospitalisation, with the variation driven by product and length of follow-up. Post-licensure real-world data have been similar or better, and tolerability has been reassuring [4]. Alongside these, Pediatrics revisits varicella in its state-of-the-art review series — a disease many trainees have never seen, now resurfacing as vaccine hesitancy rises. Naureckas Li and colleagues focus as much on the conversation as on the clinical management: how to make the case for vaccination, and how to recognise, treat, and contain varicella zoster virus when it appears [6].

Our second theme is the neonatal and early developmental period, where two papers ask what actually changes outcomes. In the European Journal of Pediatrics, Omereji and colleagues report a thirteen-year single-centre cohort of 581 infants born before twenty-nine weeks, of whom about eighty-six percent received routine probiotics and around fourteen percent did not. In-hospital mortality was under five percent in probiotic-exposed infants versus close to fourteen percent in unexposed infants, and after adjustment for gestational age, birthweight, sex, antenatal steroids and calendar year, probiotic exposure was associated with roughly a seventy percent lower odds of death, a finding that held up under propensity-score overlap weighting [3]. Importantly, there was no clear association with severe necrotising enterocolitis requiring surgery or transfer, nor with culture-positive late-onset sepsis — which is the opposite of the pattern most randomised trials have emphasised. With only seventy-nine unexposed infants, spread across a period in which two different products were used sequentially and much else in neonatal care changed, this is hypothesis-generating rather than confirmatory. Complementing that, the Journal of Pediatrics publishes Dusing and colleagues' three-arm trial of the Supporting Play Exploration and Early Development Intervention, or SPEEDI, in eighty-three infants born very preterm at a mean of twenty-six and a half weeks. Infants were randomised to early SPEEDI starting in the neonatal intensive care unit, late SPEEDI starting fifteen weeks later, or usual care. Pooling both SPEEDI arms, there was no difference from usual care — that is the headline and it should be stated plainly. But infants who started in the intensive care unit had significantly better cognitive scores than those who started later, and, after adjusting for baseline motor skills, better gross motor scores through twenty-four months, with a measurable change in parent-child dyadic interaction offering a plausible mechanism [7]. So the intervention as a whole did not beat usual care, but timing mattered within it — delaying by three months appeared to erode the benefit. In a trial of this size, that comparison is fragile, and it needs replication before we reorganise therapy services around it.

Our third theme is restraint: three papers where the honest answer is to do less, or to select more carefully. In the European Journal of Pediatrics, Kuhle and colleagues reviewed five randomised trials, nearly thirteen hundred children with a mean age of six, comparing adenotonsillectomy with watchful waiting for obstructive sleep apnoea. Spontaneous resolution occurred in between forty-four and fifty-five percent of children managed expectantly, versus fifty-seven to seventy-nine percent after surgery. Surgery reduced the apnoea-hypopnoea index more in four of five trials, but the between-group differences were modest, and the most consistent surgical advantage was in symptom scores rather than polysomnography [5]. Their conclusion is that watchful waiting for several months is defensible in young, non-obese children with mild disease, with shared decision-making and genuine follow-up, while moderate to severe obstructive sleep apnoea still warrants surgery. The Lancet Child and Adolescent Health reports the NEAT trial, a phase 3, double-blind, placebo-controlled study of erythrocyte-encapsulated dexamethasone sodium phosphate in ataxia telangiectasia, conducted at twenty sites across nine countries. Russo and colleagues randomised 105 children to six intravenous doses or placebo. Among those aged six to nine years, the primary endpoint — change in the rescored modified ataxia rating scale at six months — was not met, with a least squares mean difference of about one and a third points favouring treatment but a confidence interval crossing zero and a p-value of 0.085 [2]. Safety was good, with no treatment-related serious adverse events and no adverse signal for growth, bone mineral density, or endocrine function. After two decades of off-label corticosteroid use in this disease, this is a negative trial, and families should be counselled accordingly. The same theme of hard limits appears in a multicentre French retrospective analysis, also in the European Journal of Pediatrics, of extracorporeal cardiopulmonary resuscitation for paediatric out-of-hospital refractory cardiac arrest. Of 250 calls, 184 met the definition of refractory arrest; thirty-three met programme criteria, seventeen reached the intensive care unit in time, and thirteen were cannulated. Median low-flow time was twenty-five minutes and the median interval from arrest to extracorporeal support was eighty-two minutes. One of seventeen patients survived, and four progressed to brain death [9]. Starck and colleagues have since restricted indications in their network to selected aetiologies — a sobering counterweight to the in-hospital extracorporeal literature.

Two papers round out the week. In the European Journal of Pediatrics, Vuran and colleagues reviewed 254 children with Kawasaki disease over twenty years and found extracriteria manifestations — organ involvement beyond the five principal criteria — in about thirty percent, most often gastrointestinal. These children had higher C-reactive protein, more hypoalbuminaemia, lower sodium, and longer hospital stays, and female sex and higher C-reactive protein were independently associated with the phenotype. Crucially, coronary involvement, immunoglobulin resistance, and coronary outcomes at follow-up were no different [8]. So these presentations are a diagnostic pitfall that delays recognition in a subset, not an independent coronary risk marker. And in Pediatrics, a policy statement from O'Leary and colleagues on the school nurse's role notes that the 2024 National School Nurse Workforce Study found only about two thirds of schools have access to a full-time nurse, with disparities by school type, geography and socioeconomic status — a concrete advocacy target for paediatricians managing chronic disease, mental health and immunisation catch-up [10].

If you only have time for one paper this week, make it the influenza antiviral study in Pediatrics [1]. It addresses a decision you make dozens of times each winter, and the effect size is large enough to change your threshold for prescribing within the first forty-eight hours.

Here are the key takeaways from this week in Pediatrics. First, treat influenza early in outpatients — antiviral therapy within forty-eight hours was associated with an eighty-one percent lower hospitalisation risk across all ages studied. Second, the respiratory syncytial virus toolkit now genuinely works, with efficacy against hospitalisation reaching as high as ninety-one percent, and varicella is worth revisiting as vaccine coverage slips. Third, encapsulated dexamethasone did not improve neurological scores in ataxia telangiectasia — that trial was negative, though safe. Fourth, watchful waiting is reasonable in young, non-obese children with mild obstructive sleep apnoea, given resolution rates approaching half without surgery. And fifth, in preterm infants, engaging parents in developmental intervention appears to work best when it starts in the intensive care unit, though the pooled intervention did not beat usual care.

That's your roundup for This Week in Pediatrics. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And a quick rating on Apple Podcasts or Spotify helps other physicians discover the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.